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ing by ElAbstract Purpose: To detect the role of MR spectroscopy in evaluating the whole area of signal
alteration within the irradiated volume aiming to differentiate recurrent/residual tumors from radi-
ation injury and to detect the tumor margin and extent.
Materials and methods: This prospective study included 25 patients with previously treated primary
intracranial tumors. All patients received radiotherapy. MRI and multivoxel MRS were performed.
The volume of interest was placed over the whole area of signal alteration. The spectra were ana-
lyzed for the signal intensity of choline (Cho), creatine (Cr), and N-acetyl aspartate (NAA), lipid
(Lip), lactate (Lac), and myo-inositol (mI). Metabolite ratios for Cho/NAA, Cho/Cr, and NAA/
Cr were calculated.soura, Dakahlia, Egypt. Tel.:
A.E. Mousa).
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414 S.A. Elmogy et al.Results: Cho/NAA and Cho/Cr were signiﬁcantly higher while NAA/Cr ratios were signiﬁcantly
lower in tumors than radiation injury (p= 0.001 for all ratios). The Cho/NAA and Cho/Cr ratios
were signiﬁcantly higher in radiation injury than in normal-appearing brain tissue (p= 0.032 and
p= 0.008, respectively), whereas NAA/Cr was insigniﬁcantly lower in radiation injury than nor-
mal-appearing brain tissue (p= 0.051). Value >1.8 for Cho/NAA ratio was considered as indica-
tor for tumor.
Conclusion: MR spectroscopy can differentiate recurrent/residual tumor from radiation injury and
delineate the tumor margin and extent.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.Figure 1 Receiver operating characteristic (ROC) curve for the
cutoff value of Cho/NAA ratio (>1.8) used for differentiating
recurrent/residual tumor from radiation injury.
Table 1 Histopathology of the brain tumors included in this
study.
Histopathology No
Glioblastoma multiforme (grade IV) 12
Anaplastic astrocytoma (grade III) 5
Astrocytoma (grade II) 2
Medulloblastoma 2
Total 21
Note: the diagnosis of brain stem gliomas (n= 4) included in this
study based on their location and imaging criteria.1. Introduction
The differentiation of recurrent/residual tumor from radiation
injury after radiation therapy is often a radiologic dilemma. Of-
ten the site of the primary tumor has been subjected to radiation,
chemotherapy, and, in some instances, surgical resection, caus-
ing post treatment imaging features that are often nonspeciﬁc
and difﬁcult to interpret. MRI cannot reliably discriminate tu-
mor recurrence or progression from the inﬂammatory or necro-
tic changes resulting from radiation (1). although the latter can
be associated with more speciﬁc patterns of enhancement, such
as ‘‘soap bubble’’ or ‘‘Swiss cheese’’ enhancement (2). The two
entities may be distinguished by a brain biopsy, the patient’s
clinical course, or follow-up imaging. Among the noninvasive
methods that are available for diagnosing intracranial tumors,
which include SPECT, PET, and diffusion- and perfusion
weighted MRI, it is mainly proton MR spectroscopy that has
been used in attempts to differentiate tumor from radiation
necrosis (3–5). The gadolinium-enhancing lesion, as seen on
T1weightedMRI, reﬂects regions where there has been a break-
down of the blood–brain barrier. Thismay not be a reliable indi-
cator of active tumor due to the presence of non-enhancing
tumor tissue or contrast enhancing necrosis. Similarly, T2
deﬁned volume either overestimates or underestimates the
microscopic or non-enhancing disease in a majority of patients
(6,7). Also Yang and Aghi (8) reported that, typical MRI
appearance of radiation necrosis is a T2-hyperintense signal
and T1-enhancement after contrast administration, which is
difﬁcult to distinguish from tumor progression or ‘pseudo
progression’ (a transient increase in edema, mass effect and
contrast enhancement that resolves over time).
This study aimed to detect the role of proton MR spectros-
copy (1HMRS) in evaluating the whole area of signal alteration
within the irradiated volume, including the area of enhancement
when present, aiming to differentiate recurrent/residual tumors
from radiation injury and to detect the tumormargin and extent
in follow up of patients with post-treatment brain tumors.
2. Patients and methods
This prospective study included twenty ﬁve patients, 17 males
and eight females (age range 6–64 years; mean age, 31.2 years)
with previously treated primary intracranial tumors. In 21 pa-
tients histopathology was available (Table 1) through surgical
resection and they included: Glioblastoma multiforme (GBM)
(n= 12), anaplastic astrocytoma (n= 5), low grade astrocy-
toma (n= 2) and medulloblastoma (n= 2). The remaining
four cases were diagnosed as brain stem gliomas based on theirlocation and characteristic imaging criteria. All patients re-
ceived radiation therapy. Fourteen patients received adjuvant
chemotherapy. The mean interval between radiation therapy
and MRS was 5 months (range 3–10 months).
On follow up MRI, all patients had areas of signal alter-
ation at or near the site of the original tumor within the irra-
diated volume. MR spectroscopy was performed to all
patients in an attempt to distinguish recurrent/residual tumor
from radiation injury. Clinical, pathologic, and imaging
MR spectroscopy in post-treatment follow up of brain tumors 415follow-up after MR spectroscopy were used to establish the
nature of the lesion. Informed consent was obtained from all
patients.
Lesions were considered as recurrent/residual tumors if
they had any of the following criteria: conﬁrmation of tumor
at this site by biopsy, surgical resection; or continued progres-
sion on subsequent MRI in a manner consistent with tumor
growth. Lesions were considered as radiation injury if they
had any of the following criteria: MRI follow-up showing
prolonged stability or spontaneous regression without evi-
dence of progression on clinical and follow up imaging
evaluation. The mean follow-up time of the patients after the
MR spectroscopy was of 16 months (range 7–21 months).
2.1. MRS protocol
All MR examinations were performed on a 1.5-T scanner.
Conventional MRI was performed in conjunction with MRS
examination. Conventional MRI included: unenhanced and
gadolinium-enhanced T1-weighted images, axial T2-weighted
image and axial ﬂuid-attenuated inversion recovery (FLAIR).Figure 2 (A and B) Non enhanced and contrast enhanced axial T1
show enhancing lesion in the right parietal region. (C) Multivoxel spectr
of signal alteration, contrast-enhancing area, and the contralateral n
corresponding to the enhancing area (voxels 11, 12 and 17) show mar
with high Cho/NAA ratios (2.00–6.41) denoting residual tumor.MR spectroscopy was performed after conventional MRI
examination.
Two dimensional (2D) chemical shift image (CSI) of MRS
was acquired using a point-resolved spectroscopy sequence
(PRESS) with the following parameters: repetition time (TR)
of 1500 ms, intermediate echo time (TE) of 144 and short TE
of 35 ms, ﬁeld of view, 16 cm; matrix, 16 · 16; and slice thick-
ness, 10 mm. Outer volume fat suppression and magnetic
shimming to optimize magnetic ﬁeld homogeneity were per-
formed automatically for all patients at the beginning of exam-
ination. In addition to the routinely placed out-of ﬁeld-of-view
saturation bands, within ﬁeld-of-view saturation bands for
suppression of osseous structures and CSF-containing
structures adjacent to the tissue of interest were placed when
necessary to obtain satisfactory spectra. The full-width half-
maximum (FWHM) was kept under 10 with a ﬂip angle of
approximately 125 and water saturation between 98% and
99%, allowing separation of the choline peak from the creatine
peak.
All spectroscopic data were transferred to a separate work-
station for ofﬂine post processing using the machine software.weighted images of a previously treated glioblastoma multiforme
oscopic image with the volume of interest including the whole area
ormal-appearing brain tissue. (D) Selected spectra of the voxels
kedly elevated Cho and Lip/Lac peaks, and depressed NAA peak
416 S.A. Elmogy et al.The volume of interest (VOI) was determined by contrast-
enhanced axial T1-weighted as well as FLAIR images simulta-
neously to ensure that voxels were placed over the whole area
of signal alteration including the contrast-enhancing area
(when present), and the contralateral normal-appearing brain
tissue, which was deﬁned as not displaying signal intensity
alterations on FLAIR or T2-weighted imaging. Within the
deﬁned VOI, separate 1 · 1 · 1 cm3 voxels were placed in the
lesion; and in the contralateral normal appearing brain tissue.
The signal intensity of various metabolite peaks was
evaluated in every voxel by using the integral of each peak
as a measure of its intensity. The spectra were analyzed for
the signal intensity of choline (Cho) compounds at 3.2 ppm,
creatine (Cr) phosphocreatine at 3.02 ppm, and N-acetyl
aspartate (NAA) at 2.02 ppm, lipid (Lip) and lactate (Lac) at
0.9–1.3 ppm, myo-inositol (mI) at 3.56 ppm and glutamate
plus glutamine (Glx) at 2.05–2.5 ppm. Metabolite ratios for
Cho/NAA, Cho/Cr, and NAA/Cr were automatically calcu-
lated in the multiple voxels of whole area of signal alteration
including the contrast-enhancing area (when present), and in
the contralateral normal-appearing brain tissue. The highest
Cho/NAA, Cho/Cr, and NAA/Cr ratios in one voxel were
used for comparison. Measurements from these sites in each
patient were correlated.Figure 3 (A) Contrast enhanced axial T1 weighted image of a previo
right parietal region. (B) Multivoxel spectroscopic image and (C) selecte
26 and 30) show markedly elevated Cho and Lip/Lac peaks, and depr
residual tumor.2.2. Statistical analysis
The statistical analysis of data was done using SPSS (Statistical
Package for Social Science, version 16 Inc., Chicago, IL) pro-
gram software package for windows. The mean and SD of the
metabolite ratios for lesions diagnosed on MRS as recurrent/
residual tumors and radiation injury and the normal-appearing
brain tissue were calculated. One-way analysis of variance (AN-
OVA test) was used to compare more than two groups, and the
Student t test was used to compare between two groups. The
probability (P value) was considered signiﬁcant if 60.05 at
95% conﬁdence interval. Receiver operating characteristic
(ROC) curve was drawn to detect the best metabolite ratio
and to determine a cutoff valuewith highest sensitivity and spec-
iﬁcity that used to differentiate recurrent/residual tumor from
radiation injury. The sensitivity, speciﬁcity, accuracy, positive
predictive value (PPV), negative predictive value (NPV), and
the area under the curve were computed from the curve.
3. Results
On gadolinium-enhanced T1-weighted images, 23 cases had
enhancing lesions while two cases (one low grade glioma andusly treated glioblastoma multiforme show enhancing lesion in the
d spectra of voxels corresponding to the enhancing area (voxels 21,
essed NAA peak with high Cho/NAA ratios (3.76–6.85) denoting
Figure 4 (A and B) Multivoxel spectroscopic images at the level of posterior fossa and (C) at a higher level of a previously treated
medulloblastoma. (D) Selected spectra of the voxels: 4 in (A) and 8 and 10 in (C) show elevated Cho and Lip/Lac peaks, and depressed
NAA peak with increased Cho/NAA ratios (2.15–3.59) denoting residual tumor.
MR spectroscopy in post-treatment follow up of brain tumors 417one brain stem glioma) had no enhancing areas. MRS resulted
in high-quality spectra for choline, creatine, NAA, lipid and lac-
tate peaks in all patients. OnMRS, pathologic spectra denoting
recurrent/residual tumors were found in 16 patients (15 patients
had enhancing lesions and one had no enhancing lesion) in the
voxels placed inside the enhancing lesions (Figs. 2–4). In ﬁve of
these cases (33%), pathologic spectra denoting tumors were
also found in the voxels placed outside the areas of enhance-
ment (Figs. 5 and 6). On the other hand, the case with no
enhancing lesion on gadolinium-enhanced images, showed
spectra denoting tumor. This allowed for better delineation of
the tumor margin and extent. Spectra denoting tumors had
the following criteria: markedly elevated choline peak
(n= 12), markedly depressed NAA peak (n= 14), and ele-
vated Lip/Lac peak (n= 9). Twelve of sixteen patients
diagnosed as recurrent/residual tumors had areas denoting
associated radiation injury (Fig. 7). Nine cases were diagnosed
onMRS as pure radiation injury (Figs. 8 and 9). Spectra denot-
ing radiation injury had mild alterations in metabolite peaks
with slight elevation of choline peak, mild depression of NAA
peak and slight elevation of Lip/Lac peak. However, three cases
showed marked elevation of Lip/Lac peak. mI and Glx could
not be detected in any of the cases on short TE spectra.The mean values and ranges of the Cho/NAA, Cho/Cr, and
NAA/Cr ratios denoting recurrent/residual tumors, radiation
injury and normal-appearing brain tissue as diagnosed on
MRS are illustrated in (Table 2). There were signiﬁcantly high-
er Cho/NAA and Cho/Cr ratios with signiﬁcantly lower NAA/
Cr ratios between lesions denoting recurrent/residual tumors
and that of radiation injury (p= 0.001 for all the three ratios).
The Cho/NAA and Cho/Cr ratios were also signiﬁcantly high-
er in lesions denoting radiation injury than in normal-appear-
ing brain tissue (p= 0.032 and p= 0.008, respectively),
whereas NAA/Cr ratios were insigniﬁcantly lower in lesions
denoting radiation injury than the normal-appearing brain tis-
sue (p= 0.051). Cho/NAA ratio had the best area under the
ROC curve (0.98) with the highest sensitivity, speciﬁcity and
accuracy as compared to the other metabolite ratios (Fig. 1
and Table 3) indicating excellent differentiation between tumor
and radiation injury. The cutoff value greater than 1.8 for
Cho/NAA ratio was considered as indicator for presence of
tumor.
Fifteen of the 16 patients diagnosed on MRS as recurrent/
residual tumors proved to be correctly diagnosed based on
biopsy (n= 2), resection (n= 5), and clinical and imaging fol-
low-up data (n= 8). The remaining lesion that diagnosed on
Figure 5 (A) Contrast enhanced axial T1 weighted image of a previously treated anaplastic astrocytoma shows areas of enhancement in
the left parietal region within the irradiated volume. (B and C) Multivoxel TE 144 and TE 35 spectroscopic images respectively (D)
selected TE 144 spectra of voxels corresponding to enhancing area (voxels 2, 5 and 8) and voxels beyond the enhancing area (voxels 6 and
7) show markedly elevated Cho and Lip/Lac peaks, markedly depressed NAA peak with elevated Cho/NAA ratios (2.55–5.06) denoting
tumor recurrence. Spectrum of the voxel (1) in the normal tissue shows low Cho/NAA ratio (0.81). (E) Selected TE 35 spectrum (voxel 5)
shows absence of mI and Glx.
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Figure 6 Brain stem glioma, 7 months after radiation therapy. (A) Axial FLAIR image shows diffuse abnormal signal intensity
involving the pons. (B) Axial contrast enhanced T1 weighted image shows small area of enhancement in the left side of pons. (C)
Multivoxel spectroscopic image and (D) selected spectra of voxels placed inside (voxel 3) and outside (voxels 2 and 6) the enhancing area
show markedly elevated Cho peak, mildly elevated Lip/Lac peak and markedly depressed NAA peak with high Cho/NAA ratios (2.99–
5.58) denoting residual tumor.
MR spectroscopy in post-treatment follow up of brain tumors 419MRS as tumor, proved on biopsy to be radiation injury. This
lesion had Cho/NAA ratio of 2.87. This probably explained by
improper selection of the biopsy site. MRS correctly diagnosed
nine lesions as radiation injury as proved by biopsy (n= 2),
and clinical and imaging follow-up data (n= 7).4. Discussion
Contrast-enhancedMRI, the imaging technique used in the rou-
tine follow-up of patients with primary brain tumors is not al-
ways sufﬁcient for differentiation between radiation changes
and recurrent/residual tumors when new contrast-enhancing le-
sions are detected. Although patient with radiation changes can
be associated with more speciﬁc patterns of enhancement, both
recurrent tumors and radiation injury typically demonstrate
contrast enhancement. These patients present a diagnostic di-
lemma. Exclusion of recurrent tumor in these cases may require
invasive biopsy or resection and its attendant risks, or imaging
follow-up with a possible delay of treatment (2,9).
The results of several studies have suggested that MR spec-
troscopy is an effective tool in discriminating between postradiation changes and recurrent/residual tumors in patients
who have previously been treated for a primary intracranial
neoplasm and have quantiﬁed the alterations in MRS ratios
of Cho/NAA, NAA/Cr, and Cho/Cr associated with tumor
recurrence (10–13).
In this study, the metabolite ratios from the voxels inside
the whole area of signal alteration within the irradiated volume
including the areas of enhancement (when present), and the
contralateral normal brain tissue were evaluated. Our results
revealed signiﬁcant elevations of the Cho/NAA and Cho/Cr
ratios with a concomitant reduction in the NAA/Cr ratio in
lesions representing recurrent/residual tumors compared to
lesions representing radiation injury. Although the three
metabolite ratios signiﬁcantly predicted the presence of tumor,
Cho/NAA ratio was the best one. This was in agreement with
Smith et al. (9).
A study by Zeng et al. (12) used multivoxel 3D MR spec-
troscopy in the assessment of recurrent contrast-enhancing
areas at the site of the previously treated gliomas found that
the Cho/NAA and Cho/Cr ratios were signiﬁcantly higher in
recurrent tumor than in radiation injury, whereas the NAA/
Cr ratios were lower in recurrent tumor than in radiation
Figure 7 (A) Contrast enhanced axial T1 weighted image of a previously treated glioblastoma multiforme show enhancing lesion in the
left temporal region. (B) Multivoxel spectroscopic image and (C) selected spectra of voxels corresponding to the enhancing area (voxels 6
and 8) show elevated Cho peak, slightly decreased NAA peak and small Lip/Lac peak with low Cho/NAA ratio (1.42–1.72) denoting
radiation injury. The other spectra (voxels 10 and 11) show elevated Cho and Lip/Lac peaks, with depressed NAA peak and high Cho/
NAA ratios (3.09–4.77) denoting residual tumor in the posterior part of the lesion.
420 S.A. Elmogy et al.injury. This was in agreement with Weybright et al. (10) and
with the results of our study. Zeng et al. (12) reported also that
the Cho/NAA and Cho/Cr ratios were signiﬁcantly higher in
radiation injury than in normal-appearing brain tissue;
however, the NAA/Cr ratios were signiﬁcantly lower in radia-
tion injury than in normal-appearing white matter. Weybright
et al. (11) were in agreement with Zeng et al. (12) regarding
the Cho/NAA and Cho/Cr ratios, whereas they found insignif-
icant difference regarding NAA/Cr ratios. Our results were in
concordance with that reported by Weybright et al. (11).Many of the newly occurring lesions that are subjected to
MR spectroscopy do not consist only of pure tumor or
radiation injury/necrosis. It is assumed to be, more commonly,
a mixture of tumor cells and tissue with radiation injury
(14,15). In the current study, 12 of the 16 lesions diagnosed
on MRS as recurrent/residual tumors had areas denoting
associated radiation injury. However, the use multivoxel MR
spectroscopy enabled sampling of multiple discrete regions to
detect subtle differences between recurrent/residual tumor
and radiation injury in the same patient.
Figure 8 (A) Contrast enhanced axial T1 weighted image of a previously treated anaplastic astrocytoma shows lesion in the right parietal
region with mild central enhancement. (B) Multivoxel spectroscopic image and (C) selected spectra (voxels 2, 6 and 7) show elevated Cho
peak, slightly decreased NAA peak and small Lip/Lac peak with low Cho/NAA ratio (1.25–1.75) denoting radiation injury.
MR spectroscopy in post-treatment follow up of brain tumors 421Tumor inﬁltration into the normal tissue, beyond the con-
trast-enhanced or abnormal MR signal areas, is a well-known
phenomenon that cannot always be differentiated from edema
on T2-weighted or FLAIR images. By using MRS, it is
possible to discriminate both aspects: vasogenic edema does
not modify metabolic ratios whereas the area of cellular inﬁltra-
tion usually demonstrates increased choline anddecreasedNAA
(16). In accordancewith other studies (3,11,17), pathologic spec-
tra denoting tumor in this study were identiﬁed not only in vox-
els placedwithin the contrast-enhancing lesion but also in voxels
placed outside this area. Absence of contrast enhancement did
not exclude the presence of tumor where pathologic spectra
denoting tumor were detected in one of the two cases that
showed no enhancing areas. So, we examined the whole area
of signal alteration within the irradiated volume not only the
enhancing areas. This was beneﬁcial not only in detecting recur-
rent/residual tumor but also in deﬁning its margin and extent
that may change the options for further treatment.
Proton MRS may be readily integrated into a multi-modal-
ity MRI examination for evaluation of patients with gliomas.
In a study of 143 newly diagnosed glioma patients, MRS,
and conventional, perfusion and diffusion MRI were per-
formed before any treatment had begun. Analysis of the resultssuggested that this multi-modality approach could accurately
identify tumors of different grade, and hence be used to guide
treatment choices (18,19).
The role of commonly used advanced imaging techniques in
differentiation among intracranial masses in adults was retro-
spectively evaluated and the accuracy of MRI-based strategy
to differentiate among histologically-conﬁrmed lesions was as-
sessed. A practical MRI-based algorithm including results
from post-contrast MRI, diffusion-weighted MRI, perfusion
MRI, and 1H MRS was proposed to improve the diagnosis
and classiﬁcation of these lesions. The results suggest that inte-
gration of advanced imaging techniques with conventional
MRI help to improve the reliability of the diagnosis and clas-
siﬁcation of brain lesions (20–23). Also Chenevert and Ross
(24) and Wright et al. (25) used Diffusion indices (fractional
anisotropy and mean diffusivity) and MRS in evaluation of
tumor core, inﬁltrative growth, and normal brain tissue in
patients with gliomas. They concluded that both MRS and
diffusion tensor imaging can provide markers of inﬁltrative
tumor growth and that the combination of these two tech-
niques can improve delineation of tumor invasion.
As compared to normal brain parenchyma, tumors charac-
teristically had signiﬁcantly decreased NAA and increased
Table 3 Area under ROC curve, cutoff value, sensitivity, speciﬁcity, accuracy, PPV, and NPV of the MRS metabolite ratios.
Metabolite ratios AUC Cutoﬀ value Sensitivity Speciﬁcity Accuracy PPV NPV
Cho/NAA 0.983 1.8 0.93 [0.86; 0.97] 1 [0.95; 1.00] 0.96 [0.93; 0.98] 1 [0.95; 1.00] 0.93 [0.87; 0.97]
Cho/Cr 0.844 1.83 0.75 [0.65; 0.83] 0.89 [0.81; 0.94] 0.82 [0.76; 0.87] 0.87 [0.78; 0.93] 0.78 [0.69; 0.85]
NAA/Cr 0.184 1.105 0.66 [0.56; 0.75] 0.94 [0.87; 0.98] 0.8 [0.74; 0.85] 0.92 [0.82; 0.97] 0.73 [0.65; 0.81]
AUC= area under ROC curve, Cho = choline, Cr = creatine, NAA=N-acetyl aspartate, PPV= positive predictive value and
NPV= negative predictive value.
Figure 9 (A) Multivoxel spectroscopic image of anaplastic astrocytoma 9 months after resection and radiation.(B) Selected spectra
(voxels 5, 9 and 11) show elevated Cho and Lip/Lac peaks, mildly decreased NAA peak and low Cho/NAA ratio (1.10–1.76) denoting
radiation injury.
Table 2 Cho/NAA, Cho/Cr and NAA/Cr ratios in recurrent/residual tumors and radiation injury according to MRS diagnosis
compared to the normal appearing brain tissue.
Metabolite ratios Recurrent/residual tumors Radiation injury Normal appearing brain tissue
Cho/NAA 3.35 (1.63–6.98) 1.39 (0.85–1.76) 0.74 (0.53–1.21)
Cho/Cr 2.49 (1.57–4.17) 1.58 (0.81–2.00) 1.11 (0.82–1.35)
NAA/Cr 0.81 (0.51–1.19) 1.20 (0.83–1.65) 1.42 (0.61–2.10)
Data are mean ratios (ranges in parentheses). Cho = choline, Cr = creatine, NAA=N-acetyl aspartate.
422 S.A. Elmogy et al.choline. High amounts of free lipids, in association with high
choline, which usually indicate necrosis, are observed in high
grade lesions and metastases. Myo-inositol can be elevated ingliomas, especially low or intermediate grade lesions (WHO
grades II and III). The probability to observe lactate also in-
creases with the grade of the tumor, as the results of anaerobic
MR spectroscopy in post-treatment follow up of brain tumors 423glycolysis (14,26,27). In the present study pathologic spectra
denoting tumor had markedly elevated choline peak, markedly
depressed NAA peak, and elevated Lip/Lac peak. MI peak
could not be detected in any of the lesions.
The spectra of radiation injury in this study characterized
by mild changes in the metabolites peaks in the form of slight
elevation of choline peak, mild depression of NAA peak and
slight elevation of Lip/Lac peak except in three cases that
had marked elevation of Lip/Lac peak. Speciﬁc spectroscopic
changes that occur in radiation necrosis have been reported
(14,28–30) and include slight depression of NAA and variable
changes in Cho and Cr. In addition, radiation necrosis may
show a broad peak between 0 and 2 ppm, probably reﬂecting
cellular debris containing fatty acids, lactate, and amino acids.
Kimura et al. (31) also reported high lipid-dominant peak
along with a low Cho peak and a low NAA peak.
Different metabolite ratios with different cutoff values had
been used in differentiation of tumor and radiation injury.
Weybright et al. (11) used both Cho/Cr and Cho/NAA ratios
with cutoff value greater than 1.8 for either ratio while Zeng
et al. (12) used cutoff values of 1.71 for Cho/Cr or 1.71 for
Cho/NAA or both as tumor criteria. Narayana et al. (32) used
Cho/Cr ratio as a marker for tumor deﬁnition. In the present
study Cho/NAA ratio with cutoff value greater than 1.8 was
the best discriminator of recurrent/residual tumor and radia-
tion injury. Large prospective studies in the future using
sophisticated prediction models, new methods like 3D MRS,
and target-guided biopsies with histologic conﬁrmation are
needed to reach a consensus about the true value of MR spec-
troscopy as a method of differentiating recurrent/residual tu-
mor from radiation injury (33). The 3D MRS technique
provides full lesion coverage, higher spatial resolution, as well
as including surrounding and contralateral brain regions (34).
The limitations of our study included a relatively small
number of patients and that histopathologic diagnosis was
available in only 10 of the 25 patients. In the remaining pa-
tients, the ﬁnal classiﬁcation of recurrent/residual tumor and
radiation injury was based on clinical and imaging follow-up.
5. Conclusion
MR spectroscopy is a potential noninvasive imaging modality
that can be used in the assessment of treatment efﬁcacy in fol-
low-up of patients with brain tumors. MR spectroscopy can
differentiate recurrent/residual tumor from radiation injury
and also can delineate the tumor margin and extent, so can
contribute in treatment planning particularly for deﬁning the
target for focal therapy.References
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